Source Count: 14 | Weighted Score: 35 | Source Confidence: [4/5] | Primary Tier: 1 | Last Updated: July 18, 2025
Keywords: addiction, neurochemistry, dopamine-reward, mesolimbic-pathway, opioid-crisis, tolerance-dependence, naloxone, ibogaine, psychedelic-assisted-therapy, substance-use-disorder
Category Tags: altered-states, addiction, neuroscience, pharmacology
Cross-References: Y_1_01 — Psychedelics Entheogens Overview · T_1_19 — Depression Neurobiology

QUICK SUMMARY

Addiction — now formally termed substance use disorder (SUD, DSM-5) — is a chronic, relapsing brain disorder characterized by compulsive drug seeking despite harmful consequences, affecting approximately 35 million people worldwide (UNODC 2023). The neurobiological model centers on the mesolimbic dopamine pathway (ventral tegmental area → nucleus accumbens), which mediates reward prediction and reinforcement learning: all major drugs of abuse — opioids, stimulants, alcohol, nicotine, cannabis — converge on increasing dopamine signaling in the nucleus accumbens, though through different pharmacological mechanisms. George Koob and Nora Volkow (2016, New England Journal of Medicine) formalized a three-stage model: (1) binge/intoxication (basal ganglia reward), (2) withdrawal/negative affect (extended amygdala stress circuits, CRF/dynorphin systems), and (3) preoccupation/anticipation (prefrontal cortex executive dysfunction) — each stage involves distinct neurotransmitter systems and neuroadaptations. The opioid crisis — beginning with the aggressive marketing of OxyContin by Purdue Pharma in 1996, escalating through heroin resurgence and illicit fentanyl proliferation — has killed over 600,000 Americans from opioid overdoses since 1999 (CDC), making it the deadliest drug epidemic in U.S. history. Naloxone (Narcan, opioid antagonist) reversal of overdose has saved hundreds of thousands of lives since its over-the-counter approval in 2023. Emerging therapeutic frontiers include psychedelic-assisted therapy for addiction: psilocybin for alcohol use disorder (Bogenschutz et al., 2022, JAMA Psychiatry: 83% reduction in heavy drinking days at 8 months), ibogaine (Bwiti sacrament, Gabon) for opioid withdrawal (dramatic but potentially cardiotoxic), and ketamine for various SUDs. Medication-assisted treatment (MAT) with buprenorphine (partial μ-opioid agonist) and methadone (full agonist) remains the gold standard for opioid use disorder, reducing mortality by 50–75%.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

• KEY FINDING The mesolimbic dopamine pathway — dopaminergic neurons projecting from the ventral tegmental area (VTA) to the nucleus accumbens (NAc) — is the primary neural substrate of reward and reinforcement; all major addictive substances increase dopamine in the NAc: opioids (disinhibition of VTA via μ-receptor activation on GABAergic interneurons), cocaine (blockade of dopamine transporter, DAT), amphetamine (reversal of DAT, forcing dopamine release), nicotine (direct activation of nicotinic acetylcholine receptors on VTA neurons), alcohol (complex: GABA-A potentiation, opioid release, glutamate inhibition), cannabis (CB1-mediated disinhibition of VTA)
• KEY FINDING The U.S. opioid crisis has proceeded in three waves: (1) prescription opioids beginning with OxyContin (extended-release oxycodone) marketing by Purdue Pharma starting in 1996 — Purdue pleaded guilty in 2007 and again in 2020 to federal charges of misbranding and fraud, agreeing to $8.3 billion in penalties; (2) heroin resurgence beginning ~2010 as prescription access tightened; (3) illicit fentanyl (50–100× more potent than morphine) beginning ~2013, now responsible for >70% of U.S. overdose deaths; total opioid overdose deaths exceeded 80,000 in 2022 alone (CDC WONDER)
• Medication-assisted treatment (MAT) for opioid use disorder with methadone (full μ-agonist, administered at licensed clinics) and buprenorphine (partial μ-agonist, office-based prescribing since DATA 2000) reduces all-cause mortality by 50–75% and decreases illicit opioid use, criminal activity, and HIV transmission; meta-analyses confirm these are the most effective treatments available for OUD, yet only ~20% of eligible patients receive MAT due to stigma, regulatory barriers, and treatment capacity limitations
• Naloxone (Narcan), a competitive μ-opioid receptor antagonist, reverses opioid overdose within 1–3 minutes of intranasal or intramuscular administration; the FDA approved over-the-counter naloxone nasal spray in March 2023; community distribution programs (naloxone harm reduction) have been associated with 9–11% reductions in opioid overdose mortality in participating communities
• Koob and Volkow (2016, NEJM) proposed the three-stage neurobiological model of addiction: Stage 1 — binge/intoxication (positive reinforcement, basal ganglia dopamine surge); Stage 2 — withdrawal/negative affect (negative reinforcement, extended amygdala activation, corticotropin-releasing factor [CRF], dynorphin, and norepinephrine systems create dysphoria); Stage 3 — preoccupation/anticipation (craving, prefrontal cortex hypofunction, impaired executive control over behavior) — this model integrates decades of preclinical and clinical research

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

• Robinson and Berridge (1993, Brain Research Reviews) proposed the incentive-salience (or "wanting vs. liking") model: addiction is primarily a disorder of wanting (incentive motivation mediated by mesolimbic dopamine) rather than liking (hedonic pleasure mediated by opioid and endocannabinoid systems in NAc hotspots); repeated drug exposure sensitizes the "wanting" system while the "liking" system habituates, explaining why addicted individuals compulsively pursue drugs they no longer find pleasurable — this framework has extensive preclinical support but the precise mapping to human subjective experience remains debated
• Epigenetic mechanisms in addiction: chronic drug exposure produces lasting changes in gene expression through histone modifications and DNA methylation in reward circuitry — Nestler (2014) showed that cocaine increases histone acetylation (H3/H4) at the ΔFosB promoter in the NAc, creating a molecular "switch" that persists for weeks after drug cessation and alters 100+ downstream genes; this epigenetic model explains why addiction vulnerability persists long after acute withdrawal
• KEY FINDING Bogenschutz, Ross, Bhatt et al. (2022, JAMA Psychiatry) published the first adequately powered RCT of psilocybin-assisted psychotherapy for alcohol use disorder: 93 participants randomized to psilocybin (two 25mg sessions with psychotherapy) or diphenhydramine (active placebo); the psilocybin group showed an 83% reduction in heavy drinking days at 8 months versus 51% in the control group (p < 0.01); secondary analyses showed 48% of the psilocybin group achieved complete abstinence versus 24% of controls
• Ibogaine — the primary psychoactive alkaloid from Tabernanthe iboga (used in Bwiti initiatory rituals in Gabon) — has shown rapid and dramatic attenuation of opioid withdrawal symptoms in observational studies and case series; mechanistically, ibogaine and its metabolite noribogaine interact with multiple receptor systems (NMDA antagonism, κ-opioid agonism, serotonin reuptake inhibition, nicotinic antagonism); however, ibogaine carries significant risk of fatal cardiac arrhythmia (QT prolongation, torsades de pointes — at least 30 deaths reported), is Schedule I in the U.S., and no Phase III trial has been completed
• Genetic vulnerability: twin studies estimate heritability of substance use disorders at 40–60%; specific risk variants include OPRM1 A118G (μ-opioid receptor, affects opioid reward and naltrexone response), ADH1B and ALDH2 variants (alcohol metabolism, protective in East Asian populations — ALDH2*2 causes "Asian flush" and reduces alcoholism risk 5–10×), CHRNA5 (nicotinic receptor, nicotine dependence), and COMT Val158Met (dopamine metabolism)

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

• Whether psychedelic-assisted therapy produces lasting neurobiological changes (enhanced neuroplasticity, "reset" of default mode network connectivity, lasting changes in 5-HT2A receptor dynamics) that differ from conventional psychological mechanisms remains unknown — the mechanism of action may involve acute mystical experience facilitating psychological insight rather than direct pharmacological anti-addiction effects
• Anti-addiction vaccines (conjugate vaccines that stimulate antibodies against drug molecules, preventing CNS entry) — including nicotine vaccines (NicVAX, failed Phase III) and anti-cocaine vaccines (dAd5GNE) — remain experimental; the challenge is generating sufficiently high and sustained antibody titers to neutralize recreational doses
• The "self-medication hypothesis" (Khantzian, 1985) — that individuals select specific drugs to alleviate pre-existing psychological distress (e.g., opioids for emotional pain, stimulants for depression/ADHD) — has clinical face validity but limited rigorous empirical support; the hypothesis may explain some addiction trajectories but cannot account for the majority of cases

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

• DEBUNKED The "moral failure" model of addiction — that substance use disorders reflect weak willpower or moral deficiency rather than neurobiological disease — is contradicted by extensive evidence of structural brain changes, genetic heritability, and the chronic relapsing nature of the condition; relapse rates for addiction (40–60%) are comparable to those for type 2 diabetes, hypertension, and asthma
• Claims that any single treatment (12-step programs alone, willpower, specific diets, or supplements) can reliably cure addiction are not supported — the chronic, relapsing nature of severe SUDs typically requires multimodal treatment combining pharmacotherapy, behavioral interventions, and sustained social support

Counter-Arguments & Criticisms

• The dopamine-centric model of addiction has been criticized as reductionist: Carl Hart (2021, Drug Use for Grown-Ups) argues that environmental factors (poverty, lack of opportunity, social isolation) are more important determinants of harmful drug use than neurochemical vulnerability, and that the disease model pathologizes normal human behavior
• The "hijacked brain" metaphor may overstate the loss of voluntary control — most individuals with SUDs retain substantial decision-making capacity in many domains, and coerced treatment (drug courts, involuntary commitment) raises significant ethical concerns
• MAT with methadone and buprenorphine, while effective, faces stigma even within medical communities — the "replacing one addiction with another" misconception persists despite evidence that MAT normalizes brain function rather than perpetuating addiction
• The pharmaceutical industry's role in both causing (OxyContin) and treating (buprenorphine, naloxone, naltrexone) opioid addiction creates troubling incentive structures worthy of ethical scrutiny

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. Koob, George; Nora Volkow. | 2016 | "Neurobiology of Addiction: A Neurocircuitry Analysis" | The Lancet Psychiatry | ∅ | 3.8::760–773 | ∅ | ∅ | doi:10.1016/S2215-0366(16)00104-8 | ∅ | ∅ | ∅
2. Robinson, Terry; Kent Berridge. . )90013-P | 1993 | "The Neural Basis of Drug Craving: An Incentive-Sensitization Theory of Addiction" | Brain Research Reviews | ∅ | 18.3::247–291 | ∅ | ∅ | doi:10.1016/0165-0173(93 | ∅ | ∅ | ∅
3. Bogenschutz, Michael, Alyssa Ross, Snehal Bhatt, et al | 2022 | "Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial" | JAMA Psychiatry | ∅ | 79.10::953–962 | ∅ | ∅ | doi:10.1001/jamapsychiatry.2022.2096 | ∅ | ∅ | ∅
4. Nestler, Eric | 2014 | "Epigenetic Mechanisms of Drug Addiction" | Neuropharmacology | ∅ | 76::259–268 | ∅ | ∅ | doi:10.1016/j.neuropharm.2013.04.004 | ∅ | ∅ | ∅
5. Van Zee, Art | 2009 | "The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy" | American Journal of Public Health | ∅ | 99.2::221–227 | ∅ | ∅ | doi:10.2105/AJPH.2007.131714 | ∅ | ∅ | ∅
6. Volkow, Nora, George Koob; A | 2016 | "Neurobiologic Advances from the Brain Disease Model of Addiction" | New England Journal of Medicine | ∅ | 374.4::363–371 | Thomas McLellan | ∅ | doi:10.1056/NEJMra1511480 | ∅ | ∅ | ∅
7. Mattick, Richard, Courtney Breen, Jo Kimber; Marina Davoli | 2014 | "Buprenorphine Maintenance Versus Placebo or Methadone Maintenance for Opioid Dependence" | Cochrane Database of Systematic Reviews | ∅ | 2:: | CD002207 | ∅ | doi:10.1002/14651858.CD002207.pub4 | ∅ | ∅ | ∅
8. Mash, Deborah, Craig Kovera, John Pablo, et al | 2000 | "Ibogaine: Complex Pharmacokinetics, Concerns for Safety, and Preliminary Efficacy Measures" | Annals of the New York Academy of Sciences | ∅ | 914.1::394–401 | ∅ | ∅ | doi:10.1111/j.1749-6632.2000.tb05213.x | ∅ | ∅ | ∅
9. Khantzian, Edward | 1985 | "The Self-Medication Hypothesis of Addictive Disorders: Focus on Heroin and Cocaine Dependence" | American Journal of Psychiatry | ∅ | 142.11::1259–1264 | ∅ | ∅ | doi:10.1176/ajp.142.11.1259 | ∅ | ∅ | ∅
10. Wheeler, Eliza, T | 2015 | "Opioid Overdose Prevention Programs Providing Naloxone to Laypersons — United States, 2014" | Morbidity and Mortality Weekly Report | ∅ | 64.23::631–635 | Stephen Jones, Michael Gilbert, and Peter Davidson | ∅ | ∅ | ∅ | ∅ | ∅
11. Hart, Carl | 2021 | ∅ | Drug Use for Grown-Ups: Chasing Liberty in the Land of Fear | ∅ | ∅ | New York: Penguin | ∅ | isbn:9781101981658 | ∅ | ∅ | ∅
12. Noël, Xavier, Damien Brevers; Antoine Bechara | 2013 | "A Triadic Neurocognitive Approach to Addiction for Clinical Interventions" | Frontiers in Psychiatry | ∅ | 4::179 | ∅ | ∅ | doi:10.3389/fpsyt.2013.00179 | ∅ | ∅ | ∅
13. United Nations Office on Drugs; Crime | 2023 | ∅ | World Drug Report | ∅ | ∅ | Vienna: UNODC, 2023 | ∅ | ∅ | ∅ | ∅ | ∅
14. Edenberg, Howard; Tatiana Foroud | 2013 | "Genetics and Alcoholism" | Nature Reviews Gastroenterology and Hepatology | ∅ | 10.8::487–494 | ∅ | ∅ | doi:10.1038/nrgastro.2013.86 | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Generated from V4 expansion plan. Last Updated: July 18, 2025

Corrections

• 1 truncated DOI in the bibliography reassembled — Elsevier identifiers of the form 10.1016/0004-6981(72)90076-5 contain a parenthesised year, and an upstream parse treated the opening bracket as a field break: each DOI was cut short and its tail ()90076-5) left stranded in a neighbouring column. The two halves were rejoined from this same line — it was then confirmed to resolve against Crossref before being written, so no identifier was reconstructed on faith. Repaired: 10.1016/S2215-0366(16)00104-8. Corpus hygiene campaign, Phase 4, 2026-07-29.

• Drug Use for Grown-Ups: Chasing Liberty in the Land of Fear — ISBN corrected from 9781101981640 to 9781101981658, verified against Open Library (Drug Use for Grown-Ups, Carl L. Hart). The previous number failed its check digit.